SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Biotech Jim who wrote (2452)8/27/2010 11:55:35 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3027
 
It’s easy to over-analyze these kinds of things. If the FDA intended to demand efficacy and safety trials for MNTA’s Copaxone, the FDA would presumably not have accepted MNTA’s Copaxone ANDA for review insofar as the statutes governing ANDA reviews explicitly forbid such a request. Regards, Dew